Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Eli Lilly just reported pivotal Phase 3 results for retatrutide and the numbers are unprecedented in pharmacological obesity treatment: The Headline Numbers: 28.3% weight loss at 80 weeks (12 mg dose) 70.3 lbs average 45.3% of patients achieved 30% weight loss a threshold previously associated almost exclusively with bariatric surgery 65% of patients on 12 mg achieved non-obese BMI (BMI 18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure
These metabolic benefits occur through enhanced insulin sensitivity, reduced hepatic glucose production, and decreased caloric intake
Attendees included industry, regulators, and technologists
By following these steps, patients can enjoy the benefits of GLP-1 RAs while minimizing health risks
Regulatory and Ethical Concerns In the United States, telehealth prescribing falls under a mixture of state and federal regulations that determine the licensure of clinicians, the prescribing authority and pharmacy activities
US$ 28.18
US$ 22.19
US$ 26.41
